Company Overview

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$26.80
Change (%) Stock is Down 0.8 (2.90%)
Volume673,157
Data as of 08/21/17 4:00 p.m. ET
Refresh quote
Featured Events
Webcast
GBT at the 2016 American Society of Hematology (ASH) Annual Meeting (Replay)
12/05/16 at 12:15 p.m. PT
ASH 2016 Poster: Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor
ASH 2016 Poster: The 9-Item Sickle Cell Disease Severity Measure (SCDSM): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor
ASH 2016 Poster: Absorption, Metabolism, and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects
Corporate Presentation
Download Documentation Corporate Presentation (August 2017)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
08/09/17Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City on Wednesday, August 16 at 10:55 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section. About Global Blood Therapeutics Global Blood Therapeutics, Inc. is a clinical-stage biopha... 
Printer Friendly Version
08/07/17Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the second quarter ended June 30, 2017. "Regulatory authorities in the U.S. and EU are increasingly working to address the need for new treatment options for sickle cell disease or SCD. We support these efforts and remain committed to working collaboratively with the SCD community to bring a new and potentially disease-mod... 
Printer Friendly Version
07/26/17Global Blood Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on July 24, 2017, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 30,000 shares of the Company’s common stock with a per share exercise price of $30.25, the closing trading price on the grant date, and a restricted stock unit award for 25,000 shares of the Company’s common stock, in each case under t... 
Printer Friendly Version
07/10/17Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population
SOUTH SAN FRANCISCO, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it has expanded the ongoing HOPE-KIDS 1 Study (GBT440-007), a Phase 2a open-label study of GBT440 in pediatric patients with sickle cell disease (SCD), to include a new single-dose cohort in children age 6 to 11. “Following positive pharmacokinetic and safety results from the single-dose cohort of adolescent patients age 12 to 17, which were recently present... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.